Key Highlights

  • HEICO, Coherent, Axcelis, CarGurus, Bicara and NextDecade each show a 50-day moving average below the 200-day average.
  • HEICO's fiscal third-quarter net sales rose 23% to a record $1.41 billion, with organic growth of 14%.
  • Coherent's fiscal fourth-quarter revenue rose 33.8% to $2.05 billion, while fiscal 2026 capital spending reached $1.10 billion.
  • Axcelis guided third-quarter revenue to about $230 million, and CarGurus guided 2026 revenue growth of 10% to 13%.
  • Bicara holds $497.3 million of cash with interim trial results due mid-2027, while NextDecade targets first LNG in 2027.

A death cross occurs when a stock's 50-day simple moving average moves below its 200-day, a pattern technical analysts read as a sign of a weakening medium-term trend. It is derived from past prices and says nothing on its own about earnings quality, cash generation or clinical progress.

Six stocks across electronic technology, technology services, health technology and energy have now formed one. They range from an aerospace and electronics components maker to a clinical-stage biotechnology company and an LNG developer, so their fundamentals differ widely. Each is tested below against its latest reported results, guidance and disclosed milestones, using company releases.

Market capitalizations range from $1.20 billion at Bicara to $46.8 billion at Coherent.

Is HEICO's Death Cross Contradicted by Record Quarterly Sales?

HEICO (NYSE:HEI) is trading down 2.28% at $298.25, with a market capitalization of $35.57 billion. Fiscal third-quarter net sales rose 23% to $1.41 billion, with organic growth of 14%, and diluted earnings per share were $1.67 against $1.26.

Operating income rose 34% to $355.2 million at a 25.1% margin, and EBITDA rose 31% to $415.2 million. Flight Support Group sales rose 18% and Electronic Technologies Group sales rose 36%.

Operating cash flow was $345.3 million, up 49%. The company issued $550 million of notes due 2031 and $650 million due 2036 to repay revolver borrowings.

Total debt was $2.54 billion and net debt was $2.30 billion, or 1.57 times EBITDA. Cash paid for acquisitions was $1.02 billion over the first nine months.

Can Coherent's Revenue Surge Outweigh the Death Cross and Heavy Capital Spending?

Coherent (NYSE:COHR) is trading up 2.53% at $237.67, with a market capitalization of $46.8 billion. Fiscal fourth-quarter revenue was $2.05 billion, up 33.8%, and non-GAAP earnings were $1.74 per diluted share.

Non-GAAP gross margin was 40.2%, up 215 basis points, and Datacenter and Communications revenue was $1.62 billion. Fiscal 2026 revenue was $7.12 billion, up 22.5%.

Operating cash flow was $79.5 million in fiscal 2026, against $1.10 billion of capital expenditures. Cash and equivalents were $1.16 billion, with long-term debt of $3.21 billion.

First-quarter revenue is guided to $2.2 billion to $2.4 billion and non-GAAP earnings to $1.85 to $2.05 per share. The release does not report adjusted EBITDA.

Does Axcelis Technologies' Death Cross Overlook Higher Third-Quarter Guidance?

Axcelis Technologies (NASDAQ:ACLS) is trading up 3.29% at $116.64, with a market capitalization of $3.60 billion. Second-quarter revenue was $215.2 million, up from $194.5 million, with non-GAAP gross margin of 42.7%.

GAAP earnings were $0.75 per diluted share and non-GAAP earnings were $1.06. The chief executive said memory demand remains strong and the power market has positive momentum.

Third-quarter revenue is guided to about $230 million, with non-GAAP earnings of about $1.11 per share. The release gives no gross margin guidance.

Cash and investments were $577.0 million, while second-quarter repurchases fell to $0.2 million from $45.3 million. The release does not explain the change.

Is CarGurus' Death Cross a Margin Warning or a Buyback Story?

CarGurus (NASDAQ:CARG) is trading down 1.55% at $31.17, with a market capitalization of $2.78 billion. Second-quarter revenue rose 13% to $251.0 million, and paying dealers rose 5% to 34,629.

Adjusted EBITDA rose 7% to $84.7 million, but the margin fell 199 basis points to 34%. Non-GAAP earnings per diluted share from continuing operations were $0.66, against $0.57.

Third-quarter revenue is guided to $253.5 million to $258.5 million, and 2026 revenue growth to 10% to 13%. The company expects an adjusted EBITDA margin change of negative 0.5% to negative 1.5% for the year.

Cash was $122.1 million, down 36% since year-end, after $29.2 million of second-quarter repurchases. Total repurchases since December 2022 exceed 30% of shares outstanding.

Does Bicara Therapeutics' Death Cross Matter Ahead of a 2027 Trial Readout?

Bicara Therapeutics (NASDAQ:BCAX) is trading down 1.04% at $18.16, with a market capitalization of $1.20 billion. The clinical-stage company reported a second-quarter net loss of $55.4 million, or $0.82 per share, against $27.4 million a year earlier.

Research and development expense rose to $45.8 million from $24.8 million, driven mainly by its Phase 3 FORTIFI-HN01 trial. Cash, equivalents and marketable securities were $497.3 million, which the company says funds operations into the first half of 2029.

Topline interim results from FORTIFI-HN01, a trial in first-line HPV-negative head and neck cancer, are expected in mid-2027. The company anticipates a potential U.S. accelerated approval in that setting.

Ryan Cohlhepp becomes chief executive on January 1, 2027, succeeding Claire Mazumdar, and Jenn Larson became chief financial officer on August 12. Colorectal cancer expansion cohort data are expected in the second half of 2026.

How Far Along Is NextDecade's LNG Build Behind the Death Cross?

NextDecade (NASDAQ:NEXT) is trading down 0.32% at $6.15, with a market capitalization of $1.64 billion. Rio Grande LNG Trains 1 and 2 were 74.0% complete in June, and Train 3 was 50.4% complete.

First gas is expected in the second half of 2026 and first LNG from Train 1 in the first half of 2027. The chairman and chief executive said construction is ahead of schedule and within budget.

Train 4 was 15.5% complete and Train 5, which reached a final investment decision in October 2025, was 9.4% complete. The update describes a $1.0 billion term loan at 7.05% and $3.5 billion of senior secured notes issued in July.

The update lists no executed offtake agreements and says the company is pursuing discussions to support Train 6. It does not report a net loss, cash balance or liquidity figure.

Signal Versus Fundamentals

The six signals share a technical trigger but rest on different foundations. HEICO and Axcelis pair growth with positive cash generation or guidance, while Coherent's growth comes with capital spending far above operating cash flow.

CarGurus shows revenue growth with a narrower margin, Bicara depends on a 2027 trial readout and NextDecade on construction milestones. This comparison is limited to reported results, company guidance and disclosed milestones and does not assess valuation.